The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Amicus Therapeutics Inc shares valued at $77,518 were sold by Campbell Bradley L on Aug 01 ’24. At $10.34 per share, Campbell Bradley L sold 7,500 shares. The insider’s holdings dropped to 886,654 shares worth approximately $10.72 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, BRADLEY CAMPBELL purchased 7,500 shares, netting a total of over 77,325 in proceeds.
Before that, Campbell Bradley L had sold 6,100 shares from its account. In a trade valued at $61,029, the President and CEO traded Amicus Therapeutics Inc shares for $10.00 each. Upon closing the transaction, the insider’s holdings decreased to 6,100 shares, worth approximately $10.72 million.
As published in their initiating research note from Wells Fargo on May 30, 2024, Amicus Therapeutics Inc [FOLD] has been an Overweight and the price target has been revised to $18. Analysts at Guggenheim upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid May. As of December 19, 2023, Morgan Stanley has increased its “an Equal-weight” rating to a “an Overweight” for FOLD. Earlier on September 09, 2022, Morgan Stanley initiated its rating. Their recommendation was “an Equal-weight” for FOLD stock.
Analyzing FOLD Stock Performance
During the last five days, there has been a surge of approximately 5.13%. Over the course of the year, Amicus Therapeutics Inc shares have dropped approximately -14.80%. Shares of the company reached a 52-week high of $14.53 on 01/02/24 and a 52-week low of $9.02 on 05/13/24. A 50-day SMA is recorded $10.47, while a 200-day SMA reached $11.38. Nevertheless, trading volume fell to 2.36 million shares from 2.77 million shares the previous day.
Support And Resistance Levels for Amicus Therapeutics Inc (FOLD)
According to the 24-hour chart, there is a support level at 11.95, which, if violated, would cause prices to drop to 11.82. In the upper region, resistance lies at 12.21. The next price resistance is at 12.33. RSI (Relative Strength Index) is 72.04 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.82, which suggests the price will decrease in the coming days. Percent R is at 3.53%, indicating bullish price movement. Stochastics%K at selling indicates that the stock is to be held.
